Table 2.
STs | Target/Mediator | Effect | Cancer Type | References |
---|---|---|---|---|
ST3GAL1 | TGF-β1 | Promotion | Ovarian cancer | [57] |
ST3GAL1 | EGFR | Promotion | Ovarian cancer | [56] |
ST3GAL1 | AXL | Promotion | Melanoma | [21] |
ST3GAL1 | Promotion | HCC | [55] | |
ST3GAL3 | Integrinβ1/MMP-2/9 | Promotion | Breast cancer | [58] |
ST3GAL3/4 | Promotion | Pancreatic cancer | [59,60,61] | |
ST3GAL4 | sLex/cMet | Promotion | Gastric cancer | [62] |
ST3GAL4 | Promotion | Gastric cancer | [63] | |
ST3GAL6 | Promotion | Multiple myeloma | [64] | |
ST3GAL6-AS1 | PI3K/AKT-Foxo1 | Inhibition | Colorectal cancer | [23] |
ST6GAL1 | Integrin α5β1 | Promotion | HCC | [67] |
ST6GAL1 | Integrin β1/FAK | Promotion | HCC | [28] |
ST6GAL1 | TGF-β | Promotion | Breast cancer | [65] |
ST6GAL1 | EGFR | Promotion | Pancreatic cancer | [66] |
ST6GAL1 | PI3K/AKT/GSK3β/βcat | Promotion | Prostate cancer | [42] |
ST6GAL1 | Notch/Hes1/MMPs | Promotion | NSCLC | [68] |
ST6GAL1 | FGFR1-ERK/FAK | Promotion | Ovarian cancer | [69] |
ST6GAL1 | KAI1 | Inhibition | Colon cancer | [71] |
ST6GAL1 | ICAM1 | Inhibition | Colon cancer | [72] |
ST6GAL2 | ICAM1, VCAM1, MMP | Promotion | Breast cancer | [43] |
ST6GALNAC1 | sTn-CD44/MUC1 | Promotion | Gastric cancer | [73] |
ST6GALNAC1 | IGF-1/STAT5b | Promotion | Gastric cancer | [74] |
ST6GALNAC1 | PI3K/AKT/NF-kB | Promotion | HCC | [44] |
ST6GALNAC2 | Galectin-3 | Inhibition | Breast cancer | [76] |
ST6GALNAC2 | PI3K/AKT/NF-kB | Promotion | Breast cancer | [77] |
ST6GALNAC2 | PI3K/AKT/NF-kB | Promotion | Thyroid carcinoma | [78] |
ST8SIA1 | cMet | Promotion | Breast cancer | [79] |
ST8SIA1 | FAK-AKT-mTOR | Promotion | TNBC | [80] |
ST8SIA4 | Promotion | Breast cancer | [34] | |
ST8SIA4 | Inhibition | Thyroid carcinoma | [35] | |
ST8SIA6-AS1 | p38 | Promotion | Breast cancer | [47] |
ST8SIA6-AS1 | DCAF4L2 | Promotion | HCC | [46] |
ST8SIA6-AS1 | miR-125a-3p/NNMT | Promotion | Lung adenocarcinoma | [36] |